Real-world effectiveness of imeglimin in patients with type 2 diabetes: A retrospective longitudinal study in Japan

Abstract

ObjectiveTo examine the real effects of imeglimin on glycemic control and other metabolic factors in patients with type 2 diabetes (T2DM). MethodsA retrospective longitudinal study was conducted based on a chart review. We recruited patients with T2DM who took imeglimin continuously for at least 3 months. Data on various metabolic parameters were collected at the first prescription of imeglimin and at 3, 6 and 12 months after the initiation of imeglimin. Statistical comparisons were performed using paired t-tests. Results68 patients were eligible for this study. HbA1c decreased by 0.7 % at 3 months, 1.1 % at 6 months and 1.0 % by 12 months after the initiation of imeglimin. The decreases in HbA1c were observed regardless of age, gender, body mass index, duration of diabetes, renal function and concomitant use of hypoglycemic agents. There were also significant decreases in body weight, low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C) and non-HDL-C during imeglimin treatment. ConclusionsThis is the first report showing the long-term effects of imeglimin in a real-world setting. We confirmed the glucose-lowering effects of imeglimin in a real-world clinical setting. Furthermore, favorable effects of imeglimin on body weight and serum lipids were also suggested.